IRIDEX CORP (IRIX) Earnings History

IRIDEX CORP - Q4 FY2025 Earnings

Filed at: Jan 11, 2026, 7:00 PM EST|Read from source

EXECUTIVE SUMMARY

IRIDEX Corp. demonstrated a strong finish to 2025, marked by accelerating revenue growth, positive cash flow in the fourth quarter, and an expected positive adjusted EBITDA for the full year. The company attributes these improvements to focused cost reductions, gross margin expansion, and enhanced commercial efficiency, particularly in probe sales.

POSITIVE HIGHLIGHTS

  • •

    Fourth quarter total revenue expected to be between $14.6 million and $14.8 million, representing year-over-year growth between 15% and 17%.

    positive
  • •

    Achieved positive cash flow in the fourth quarter of 2025.

    positive
  • •

    Full year 2025 total revenue expected to be between $52.5 million and $52.7 million, representing year-over-year growth of 8%.

    positive
  • •

    Company expects to achieve positive adjusted EBITDA for the full year 2025.

    positive
  • •

    Sold 15,800 Cyclo G6® probes in Q4 2025, compared to 13,300 in the prior year quarter.

    positive
  • •

    Sold 57,700 Cyclo G6® probes for the full year 2025, compared to 55,400 in the prior year.

    positive

CONCERNS & RISKS

  • •

    Sold 44 Cyclo G6 Glaucoma Laser Systems in Q4 2025, compared to 47 in the prior year quarter, indicating a slight decline in system sales.

    attention
  • •

    Sold 133 Cyclo G6 Glaucoma Laser Systems for the full year 2025, compared to 125 in the prior year, showing modest growth in system sales.

    attention

FINANCIAL METRICS

Revenue
Quarterly
$14.70M
+15.8%
Prior year: $12.70M
Annual (YTD)
$52.60M
N/A
Prior year: $48.70M
Net Income
Quarterly
N/A
N/A
EPS (Diluted)
Quarterly
N/A
N/A
Prior year: $-0.09
Operating Income
Quarterly
N/A
N/A
EPS (Basic)
Quarterly
N/A
N/A

MARGIN ANALYSIS

Operating Margin
Current Quarter
N/A
Prior Year
-11.3%
YoY Change
N/A

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

REVENUE BY SEGMENT — Q4 FY2025 2025

VISUAL OVERVIEW

|
Glaucoma
0.0%
N/A

DETAILED BREAKDOWN

|
SegmentCurrentPrior YrYoY% Total
Glaucoma
N/A———
Total Revenue$0.00M——100.0%

Segment performance shows business unit health and growth drivers.

MANAGEMENT COMMENTARY

Strengthened our financial position through focused cost reductions, gross margin expansion, and improved commercial efficiency, and increased probe sales.

— IRIDEX CORP, Q4 FY2025 2025 Earnings Call

In 2025 we delivered on our goals, driving a fifth consecutive quarter of year-over-year revenue growth, reduced operating expenses, and improved adjusted EBITDA.

— IRIDEX CORP, Q4 FY2025 2025 Earnings Call

Achieved positive cash flow in the fourth quarter of 2025, and we expect to achieve positive adjusted EBITDA for the full year 2025.

— IRIDEX CORP, Q4 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

Cyclo G6 Glaucoma Laser Systems
44
-6.4% YoY
Prior year: 47
systems
Cyclo G6® probes
15.8K
+18.8% YoY
Prior year: 13.3K
probes

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.